In prostate cancer cells, OR51E2 activation results in an activation of protein tyrosine kinase 2 beta (Pyk2), which in turn leads to the phosphorylation of p38 mitogen-activated protein kinases (Neuhaus et al., 2009; Wiese et al., 2015). This evidence concerns the gene MAPK14 and prostate carcinoma.